Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX111 in Advanced Solid Tumors and Lymphoma
NCT07333469Phase 2Not yet recruiting
- Sponsor
- Hanx Biopharmaceuticals
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of HX111 in solid tumor, lymphoma, sponsored by Hanx Biopharmaceuticals. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
HX111
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT07333469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333469.